Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03726307 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study
A Phase 1 study of Kidney Transplant and Renal Transplant Recipients, sponsored by Angus W. Thomson PhD DSc.
- Active
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03726307 is a Phase 1 study of Kidney Transplant and Renal Transplant Recipients that is active but no longer recruiting, run by Angus W. Thomson PhD DSc. The registered enrollment target is 28 participants, below the 1,897-participant average among 30 other Kidney Transplant trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03726307, a Phase 1 study of Kidney Transplant and Renal Transplant Recipients, is active but no longer recruiting, sponsored by Angus W. Thomson PhD DSc.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and feasibility of treatment involving a single infusion of donor-derived regulatory dendritic cells (DCreg) in first time, living donor renal transplant recipients. DCreg will be prepared from monocytes obtained by leukapheresis from prospective (non-mobilized) living kidney donors and infused into the respective recipients 7 days before renal transplantation. This study will enroll 28 subjects (14 recipients, 14 donors). The duration of follow-up will be: * 1 week following the leukapheresis procedure for donors and * 2 years following their DCreg infusion for kidney recipients.
Conditions Studied
Interventions
- BIOLOGICAL DCreg: 0.5 million cells/kg+SOC
- BIOLOGICAL DCreg: 1.2 million cells/kg+SOC
- BIOLOGICAL DCreg:2.5 to 5.0 million cells/kg+SOC
Study Locations (1)
Pennsylvania
- University of Pittsburgh, Starzl Transplantation Institute - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-04-10 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03726307
The ClinicalTrials.gov registry entry for NCT03726307 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,897-participant average among 30 other Kidney Transplant trials with a reported enrollment target (99% lower). The listed sponsor is Angus W. Thomson PhD DSc, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kidney Transplant appearing as the primary indexed condition, and to 3 interventions - of which DCreg: 0.5 million cells/kg+SOC is the first listed.
NCT03726307 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03726307 about?
NCT03726307 is a clinical study titled "Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study". This study will evaluate the safety and feasibility of treatment involving a single infusion of donor-derived regulatory dendritic cells (DCreg) in first time, living donor renal transplant recipients. DCreg will be prepared from monocytes obtained by leukapheresis from prospective (non-mobilized) ...
What is the current status of trial NCT03726307?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2019-04-10. Estimated completion is 2027-03.
What conditions does trial NCT03726307 study?
This clinical trial studies the following conditions: Kidney Transplant, Renal Transplant Recipients.
What interventions are being tested in trial NCT03726307?
The interventions under investigation include: DCreg: 0.5 million cells/kg+SOC (BIOLOGICAL), DCreg: 1.2 million cells/kg+SOC (BIOLOGICAL), DCreg:2.5 to 5.0 million cells/kg+SOC (BIOLOGICAL).
Who is sponsoring clinical trial NCT03726307?
This trial is sponsored by Angus W. Thomson PhD DSc, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03726307 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients
RECRUITING · Phase 1
-
Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor
RECRUITING · Phase 1
-
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
RECRUITING · Phase 1
-
TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
Social Support Counseling Intervention for Kidney Transplant Candidates
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.